---
document_datetime: 2026-01-23 10:36:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ontruzant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ontruzant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7252339
conversion_datetime: 2026-01-26 20:30:45.116272
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ontruzant

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 22/01/2026                          |                                             | SmPC,                            | To update Sections 2, 4.4, and 6.1 of the SmPC, |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000320521                     | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Sections 2, 4.4, and 6.1 of the SmPC, Section 3 of the Labeling, and Sections 2 and 6 of the PL, to include information regarding polysorbates used as excipients in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use', following approval of the same change for the reference product. In addition, the MAH took the opportunity to implement minor editorial changes in line   |            |     | Labelling and PL   | Section 3 of the Labeling, and Sections 2 and 6 of the PL, to include information regarding polysorbates used as excipients in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use', following approval of the same change for the reference product. In addition, the MAH took the opportunity to implement minor editorial changes in line with the QRD template.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000290110 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/08/2025 | N/A |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Variation type IB / EMA/VR/0000263761 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/04/2025 | N/A |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|